FDA Calls for Public Comments on Wider Distribution of Naloxone for Opioid Overdose Fatality Prevention

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), in collaboration with the Office of the Assistant Secretary for Health, National Institutes of Drug

Abuse, and the Centers for Disease Control and Prevention, is announcing a scientific workshop to initiate a public discussion about the potential value of making naloxone more widely available outside of conventional medical settings to reduce the incidence of opioid overdose fatalities.

http://www.gpo.gov/fdsys/pkg/FR-2011-11-17/pdf/2011-29703.pdf

Source: Federal Register / Vol. 76, No. 222 / Thursday, November 17, 2011 / Notices

Comments

  1. Kristine Tures says

    I currently work in Methadone Maintenance Therapy and a Harm Reduction Model facility. This concept of providing naloxone in an unconventional manner is an idea that is long overdue. As we all know Opioid addiction issues have reached epidemic levels, with the younger populations be hardest hit. Individuals are starting out with opiate narcotic pain relievers and then quickly realize the it is easier and cheaper to attain heroin. The potency of heroin is high and many times individuals are using more or with greater frquency, even combining with a benzo which makes for a dealy combination. Providing additional resources or services to the opioid addicted population is needed and desired by the addicts themselves.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>